GlobeNewswire by notified

Tryg Forsikring A/S mandates potential SEK/NOK/DKK Restricted Tier 1 PNC5 Notes (corrected text with reference to the purchase of the Existing Notes)

Share


Tryg Forsikring A/S (the “Issuer”), rated A1 by Moody’s, has mandated Danske Bank and Nordea as Joint Lead Managers to arrange a digital fixed income investor meeting on Monday 6 March 2023 at 14:00 CET, and to explore subsequent issuance of one or more Perpetual Restricted Tier 1 Capital Notes (the “Notes”). The Notes may be denominated in any of the Nordic currencies and carry a fixed and/or variable rate of interest for the targeted 5 year maturity to first call, subject to market conditions. The Notes are expected to be rated Baa3 by Moody’s and will feature a principal write-down loss absorption mechanism with a discretionary reinstatement condition.

In connection with the contemplated issuance of the Notes, the Issuer is contemplating to purchase some or all of its outstanding SEK 700,000,000 Floating Rate Perpetual Restricted Tier 1 Capital Notes (kapitalbeviser) with ISIN DK0030418249 (the “Existing Notes”) on the secondary market. Any purchase by the Issuer of Existing Notes will be executed in the absolute and sole discretion and determination of the Issuer and any such purchase shall be conditional upon (i) the successful completion of the issuance and settlement of the Notes, (ii) receipt by the Issuer of the proceeds of the issuance of the Notes, (iii) that the Issuer’s purchase of the Existing Notes is funded out of the proceeds of the Notes and (iv) the satisfaction of each of the Redemption and Purchase Conditions as set out and as defined in the terms and conditions of the Existing Notes (together the “Purchase Conditions”). The Danish Financial Supervisory Authority has given its pre-approval to the Issuer’s purchase of the Existing Notes. The purchase price for any such purchase of Existing Notes will be announced when determined by the Issuer, expectedly in conjunction with the announcement of pricing of the contemplated issue of the Notes.

MIFID II product governance / Professional investors and eligible counterparties only target market / No PRIIPs KID: The target investors of the Notes are only eligible counterparties and professional clients (all distribution channels). No packaged retail and insurance-based investment products ("PRIIPs") key information document ("KID") has been prepared as the Notes are not available to retail investors in the European Economic Area or the United Kingdom.


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Multitude Group Annual Report for 2022 published30.3.2023 22:45:00 CEST | Press release

Multitude Group Annual Report for 2022 published Helsinki, 30 March 2023 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or the “Group”) is pleased to announce that the Group's Annual Report, Corporate Governance Statement and Remuneration Report for the year ended 31 December 2022 have been published today on the company’s website. The Annual Report consists of annual review and financial review, including Board of Directors‘ report, consolidated financial statements and parent company’s financial statements. The annual review includes the ESG Report 2022 which comprises the non-financial statement. It outlines the Group’s ESG Goals and KPIs focused on people, processes, and the environment, with commencement of reporting on the Group’s carbon emissions. The ESG report 2022 further highlights the Group’s commitment to customer well-being through responsible lending practices and the introduction of a Responsible Lending Index and a commitment to progress on employee well

Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion30.3.2023 22:45:00 CEST | Press release

Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS. As announced on 30 March 2023, Zealand Pharma commenced

Multitude SE: Notice to Convene Multitude SE's Annual General Meeting of Shareholders30.3.2023 22:45:00 CEST | Press release

NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is given to the shareholders of Multitude SE (Company) that the Annual General Meeting of the Company is to be held on 27 April 2023 at 10:00 a.m. (EEST / Finnish time) at the offices of Castrén & Snellman Attorneys Ltd, Eteläesplanadi 14, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will start at 9:30 a.m. (EEST / Finnish time). Shareholders may also exercise their voting rights by voting in advance. Instructions concerning advance voting are provided in Section 3.4 of this notice. It will not be possible to participate in the meeting or follow the meeting via an online stream or otherwise in real time by the use of telecommunication connections or technical means. The meeting will be held in the English language. 1 MATTERS ON THE AGENDA OF THE GENERAL MEETING OF SHAREHOLDERS At the General Meeting of Shareholders, the following matte

Galapagos and NovAliX enter into an integrated drug discovery collaboration30.3.2023 22:30:00 CEST | Press release

Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, FranceNovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access necessary expertise and resources through a five year-collaboration agreementTransaction in the context of Galapagos’ strategic reset announced in 2022; closing expected in July 2023 Mechelen, Belgium and Strasbourg, France; 30March 2023, 22.01 CET; GalapagosNV (Euronext & NASDAQ: GLPG)and NovAliXtoday announceda strategic collaborationin which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientationof the company into a fit-for-purpose

ResMed Chief Administrative Officer and Global General Counsel to Retire30.3.2023 22:05:00 CEST | Press release

ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will conduct an internal search for the successor to Pendarvis’ legal roles and expects to name a new global general counsel and secretary well ahead of David’s retirement date to ensure a smooth and seamless transition. Amy Wakeham, ResMed’s current Vice President of Corporate Communications & Investor Relations, has been appointed Chief Communications and Investor Relations Officer to succeed Pendarvis in his role leading corporate public affairs; she will report to the Office of the CEO and will jo